Bacteria in a tumour’s microbiome could influence how cancer responds to treatment
US researchers find that bacteria could help tumours progress and resist treatment.
List view / Grid view
US researchers find that bacteria could help tumours progress and resist treatment.
US researchers have utilised a cancer immunotherapy technique, CAR-T cell method to effectively eliminate SARS-CoV-2 virus pre- and post-infection in vitro.
This article highlights five of the latest findings revealed using CRISPR that could be used in the development or design of new therapies.
Drug Target Review’s Ria Kakkad recently travelled to Barcelona to attend PEGS Europe’s Protein and Antibody Engineering Summit. In this article, she shares her highlights from the event.
US scientists, using CRISPR technology, removed specific genes in humans to allow the immune system to be more activated against cancer.
Researchers have developed a new method for comparing CAR T cells, each with slightly different molecular features, to determine which is most effective and long-lasting against cancer.
A new pre-clinical study has utilised nanoparticles to attach immune-activating molecules to cancer cells.
NIH researchers who intravenously delivered a cancer vaccine to mice report that it increased the number of T cells able to combat tumours.
A UNIGE team reveals that a drug used against herpes can fight a bacterium that is resistant to most antibiotics by weakening its defence mechanisms.
Using DNA barcoding to track cancer cells through time, scientists have shown that the cells have diverse abilities to escape the immune system.
Pre-clinical experiments involving cells from ICUs patients infected by SARS-CoV-2, and mice infected by MHV-A59 (murine hepatitis virus A59) show promise in treating COVID-19.
Researchers have discovered a new cancer immunotherapy approach that shrinks solid tumours.
Dr Larysa Baraban, physicist at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) is researching a chip that should ultimately make it possible to develop personalised cancer immunotherapies.
Researchers have eradicated malignant tumours in mice by combining an immunotherapy agent with a molecular delivery system that targets tumour acidity.
Using cryo-EM, the researchers found that the B-cell receptor interacts with further receptors, thus controlling its signal transduction.